RT Journal Article
SR Electronic
T1 Impact of the COVID-19 pandemic on antidiabetic drugs initiation in Sweden, an interrupted time series study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.09.24307137
DO 10.1101/2024.05.09.24307137
A1 Khanyk, Nataliia
A1 Nyberg, Fredrik
A1 Wettermark, Björn
A1 Li, Huiqi
A1 Eeg-Olofsson, Katarina
A1 Gudbjornsdottir, Soffia
A1 Hajiebrahimi, Mohammadhossein
YR 2024
UL http://medrxiv.org/content/early/2024/05/10/2024.05.09.24307137.abstract
AB Aim To investigate the impact of the COVID-19-pandemic on antidiabetic drug initiationMethods Using Swedish national health registers, an interrupted time series study for all first-time dispensed antidiabetic drugs was performed. A minimum 14-month washout period was used. We calculated monthly cumulative incidence of antidiabetic drug initiations per 1000 population and estimated trends before and after the onset of the pandemic using segmented regression analysis.Results Among 167,889 participants between 1Mar2019 and 30Nov2021, male sex (53%), age 18-64 (55.3%), unmarried status (52.5%), upper secondary education level (46.2%), and being employed (53.5%) were the most frequent characteristics. Mar2020, there was an immediate level drop in antidiabetic drug initiation (β2=-0.087%, P=0.01); however, the trend exhibited a rapid increase thereafter. Significant immediate level drops were identified for DPP4i (−0.087%, P=0.01), GLP1a (−0.008%, P=0.01) and SGLT2i (−0.033%, P=0.003). Older people (≥65) showed the largest immediate drop for antidiabetic drug initiation (−0.272%, P=0.003). SGLT2i demonstrated an increasing pattern both before and after the pandemic while metformin did reveal an increasing pattern among patients ≥65 years old after the pandemic.Conclusion The results identified an immediate level drop at the onset of the pandemic for any antidiabetic drug initiation, but the trend increased rapidly thereafter.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research has ethics approval from the Swedish Ethical Review Authority (2020-01800 with subsequent amendments)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data underlying this article cannot be shared publicly due to their containing sensitive information that could compromise the privacy of research participants. Analysis data will be shared upon reasonable request to the authors. Access to similar data requires permission. Apart from ethical approval from the Swedish Ethical Review Authority, researchers will also need approval from each register holder.